From Wikipedia, the free encyclopedia
Monoclonal antibody
Flotetuzumab (
INN;
[1] development code MGD006) is a bispecific antibody
[2] designed for the treatment of
acute myeloid leukemia.
[3]
[4]
This drug is being developed by MacroGenics, Inc.
[5]
References
-
^
World Health Organization (2017).
"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
-
^ Guy DG, Uy GL (October 2018).
"Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia". Curr Hematol Malig Rep. 13 (6): 417–425.
doi:
10.1007/s11899-018-0472-8.
PMC
6295344.
PMID
30280288.
-
^ Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE (June 2018).
"Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity". Clin. Cancer Res. 24 (11): 2631–2641.
doi:
10.1158/1078-0432.CCR-17-2265.
PMID
29463552..
-
^ Assi R, Kantarjian H, Ravandi F, Daver N (March 2018). "Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors". Curr. Opin. Hematol. 25 (2): 136–145.
doi:
10.1097/MOH.0000000000000401.
PMID
29206680.
S2CID
23901088.
-
^
Statement On A Nonproprietary Name Adopted By The USAN Council - Flotetuzumab,
American Medical Association.